Insider · CIK 0001745285
Evan Kearns
Files at COGT (Cogent Biosciences, Inc.). First filing Dec 30, 2025, latest Dec 30, 2025.
Evan Kearns files SEC Form 4 as officer at COGT (Cogent Biosciences, Inc.). Since Dec 30, 2025, Evan Kearns has reported 0 open-market buys worth $0 and 1 open-market sell worth $2.5M, the latest filed on Dec 30, 2025.
A track record needs three past buys with six months of prices behind them; Evan Kearns has 0, so none is measured yet.
The newest scored trade: sold $2.5M of COGT on Dec 26, 2025, filed Dec 30, 2025, scored 65 (notable). In the last 12 months: 0 buys worth $0 and 1 sell worth $2.5M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
COGT: Cogent Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 65Notable | Cogent Biosciences, Inc. | $2.5M 65,000 shares | -37% | +867% from low-8% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 29, 2025 | COGT COGENT BIOSCIENCES, INC. | 65,000 0.05% of outstanding | $2.5M | Dec 26, 2025 | none |
Transactions
Every row this insider has filed, 6 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 26, 2025 | COGT Cogent Biosciences, Inc. | SOpen-market sale Common Stock | -65,000 | $38.70 | $2.5M | 109,398 | Dec 30, 2025 |
| Dec 17, 2025 | COGT Cogent Biosciences, Inc. | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 40,000 | Dec 19, 2025 |
| Dec 17, 2025 | COGT Cogent Biosciences, Inc. | AGrant or award Common Stock | +260,000 | $0.00 | $0 | 300,000 | Dec 19, 2025 |
| Dec 17, 2025 | COGT Cogent Biosciences, Inc. | FTax withholding Common Stock | -125,602 | $39.45 | $5.0M | 174,398 | Dec 19, 2025 |
| Dec 17, 2025 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +55,000 | $0.00 | $0 | 55,000 | Dec 19, 2025 |
| Jan 23, 2025 | COGT Cogent Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +230,000 | $0.00 | $0 | 230,000 | Jan 27, 2025 |
Questions about Evan Kearns
Answered from the filings on this page, as of the latest one.
Is Evan Kearns buying or selling?
In the last 12 months Evan Kearns reported 0 open-market buys worth $0 and 1 open-market sell worth $2.5M on SEC Form 4; the latest was sold $2.5M of COGT on Dec 26, 2025. Grants, option exercises and tax withholding are not counted.
How did Evan Kearns's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Evan Kearns has 0.
Where does Evan Kearns file Form 4?
Evan Kearns has filed Form 4 at COGT (Cogent Biosciences, Inc.) as Chief Legal Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.